Dabrafenib/trametinib

Dabrafenib/trametinib Reactions 1704, p130 - 2 Jun 2018 Blurred vision, nausea and peripheral oedema: case report A 51-year-old woman developed occasional nausea, peripheral oedema and blurred vision following treatment with dabrafenib and trametinib [time to reactions onsets not stated]. The woman, who was diagnosed with an anaplastic ganglioglioma (WHO grade III), underwent surgery and began adjuvant radiotherapy. However, 8 days following surgery, a repeat MRI study of her brain and spine revealed tumour progression with extensive leptomeningeal disease. Later, she was considered for combination therapy of radiation with BRAF and MEK inhibitors, dabrafenib and trametinib, respectively. She received eight 30 day cycles of oral dabrafenib 150mg twice daily and oral trametinib 2mg daily. She developed mild side-effects during the treatment. She reported occasional nausea, which was adequately controlled with ondansetron. She also developed peripheral oedema in the arms and legs as well as blurred vision, which improved over the time period. Three months following therapy, MRI demonstrated a marked reduction in the tumour burden, which was stable at 6 months. Also, she showed significant improvement in her functional status. Author comment: "The therapy was overall well-tolerated, with mild and expected side effects. She complained of occasional nausea, which was adequately controlled with Ondansetron. She also described some peripheral edema in the arms and legs as well as blurred vision, which improved over time." Beland B, et al. Unprecedented response to combination BRAF and MEK inhibitors in adult anaplastic ganglioglioma. Journal of Neuro-Oncology 137: 667-669, No. 3, May 2018. Available from: URL: http://doi.org/10.1007/ s11060-018-2760-5 - Canada 803323916 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Dabrafenib/trametinib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/dabrafenib-trametinib-F3C2LYBFs9
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46773-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p130 - 2 Jun 2018 Blurred vision, nausea and peripheral oedema: case report A 51-year-old woman developed occasional nausea, peripheral oedema and blurred vision following treatment with dabrafenib and trametinib [time to reactions onsets not stated]. The woman, who was diagnosed with an anaplastic ganglioglioma (WHO grade III), underwent surgery and began adjuvant radiotherapy. However, 8 days following surgery, a repeat MRI study of her brain and spine revealed tumour progression with extensive leptomeningeal disease. Later, she was considered for combination therapy of radiation with BRAF and MEK inhibitors, dabrafenib and trametinib, respectively. She received eight 30 day cycles of oral dabrafenib 150mg twice daily and oral trametinib 2mg daily. She developed mild side-effects during the treatment. She reported occasional nausea, which was adequately controlled with ondansetron. She also developed peripheral oedema in the arms and legs as well as blurred vision, which improved over the time period. Three months following therapy, MRI demonstrated a marked reduction in the tumour burden, which was stable at 6 months. Also, she showed significant improvement in her functional status. Author comment: "The therapy was overall well-tolerated, with mild and expected side effects. She complained of occasional nausea, which was adequately controlled with Ondansetron. She also described some peripheral edema in the arms and legs as well as blurred vision, which improved over time." Beland B, et al. Unprecedented response to combination BRAF and MEK inhibitors in adult anaplastic ganglioglioma. Journal of Neuro-Oncology 137: 667-669, No. 3, May 2018. Available from: URL: http://doi.org/10.1007/ s11060-018-2760-5 - Canada 803323916 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off